Newport Beach, CA - September 15, 2003

Biosensors to Debut Investigational Cardiac Stent
Live by Satellite at TCT Conference

Biosensors International today announced details of its participation in this year's TCT Annual Conference, being held at the Washington Convention Center Monday, September 15 through Friday, September 19 in Washington, DC. This is one of the premier events in the rapidly evolving world of cardiology, and annually attracts the world's foremost cardiovascular practitioners, researchers and medical device manufacturers for presentations on a wide range of current topics in the field.

Highlighting this year's TCT Conference will be a live case transmission of the first-ever implantation in a human subject of Biosensors' investigational MATRIXT drug-eluting stent ("DES"), which is designed to restore blood flow in a patient's constricted artery. The procedure will be transmitted live by satellite from Siegberg Heart Center in Germany.

The MATRIXT stent is designed to combat the common post-surgical side-effect of stent implantation called restenosis, in which the body's natural reaction to implantation of a foreign object can result in excessive tissue build-up around it, reversing the therapeutic effect of the stent. MATRIXT releases (or "elutes") the candidate anti-proliferative drug Biolimus A-9, developed by Biosensors, into the tissue surrounding the stent to prevent restenosis, thus safeguarding the stent's restoration of normal blood flow. Biolimus is an analog of drugs previoiusly approved for this application, but has exhibited bioavailability superior to other drugs in its class in preliminary studies.

Throughout the week, Biosensors executives will be meeting with conference attendees at Booth 1720, Exhibit Hall Lower Level, near the poster presentations area.

In addition, John Shulze, the Company's Chief Technology Officer and a TCT faculty member, will present a lecture on Friday, "Bioerosion in Ultrathin PLA Drug Composite Is Safe and Effective" as part of the Conference's Drug-Eluting Stent Summit. Special coating composites for stents are essential to controlling the rate of release of the drugs they elute, such as Biolimus A-9, and John Shulze heads the Biosensors initiative that leverages the Company's expertise in this field.

"Last year's TCT conference marked a milestone in our development program for the drug-eluting stent, trade-named Challenge, which we subsequently licensed to Guidant Corporation, and which is now the centerpiece of Guidant's DES initiative," commented Yoh-Chie Lu, President and CEO of Biosensors International. "We are pleased and proud to share our ideas and accomplishments with the leading cardiologists and researchers who attend TCT."

Mr. Lu continued, "This year's TCT is even more noteworthy for us, with the first implantation in a human subject of our new, investigational MATRIXT DES, in a procedure that will be shown to hundreds of attendees of this large-scale, prominent cardiovascular conference. We are looking forward to renewing contact with many of the participants in last year's conference and to making some new friends as well."

Biosensors focuses its research in the fields of new drug discovery, stent design and local drug delivery coating development for interventional cardiology markets worldwide. Biosensors International is a subsidiary of Biosensors International Group, and seeks to become a leading company specializing in cardiovascular technology. Its manufacturing facilities are certified by world authorities such the FDA, TGA, ISO and CE Mark.

For more information, please visit http://www.biosensors.com.sg. Live streaming video of the MATRIXT surgery will be available at that site shortly following completion of the procedure.

U.S. Contact:
Biosensors International USA, (949) 553-8300

InvestorInfo@Biosensors-usa.com

Media Relations contact: Sean Collins, CCG, (818) 789-0100 or (310) 497-9205; or Valerie Bent, (702) 270-9696.